Atyr PHARMA (ATYR) Stock Price, News & Analysis

Company Overview

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $2.95 to $3.19
• 50-Day Range: $1.72 to $3.52
• 52-Week Range: $1.14 to $3.80
• Volume: 1.27 million shs
• Average Volume: 925,574 shs
• Market Capitalization: $254.34 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $19.25
• Consensus Rating: Buy

Atyr PHARMA Stock Analysis - MarketRank™

Atyr PHARMA scored higher than 40% of companies evaluated by MarketBeat, and ranked 538th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Atyr PHARMA has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Atyr PHARMA has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Atyr PHARMA are expected to grow in the coming year, from ($0.89) to ($0.87) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Atyr PHARMA is -3.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Atyr PHARMA is -3.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Atyr PHARMA has a P/B Ratio of 3.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.03% of the float of Atyr PHARMA has been sold short.

Short Interest Ratio / Days to Cover

Atyr PHARMA has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Atyr PHARMA has recently increased by 55.14%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Atyr PHARMA does not currently pay a dividend.

Dividend Growth

Atyr PHARMA does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.03% of the float of Atyr PHARMA has been sold short.

Short Interest Ratio / Days to Cover

Atyr PHARMA has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Atyr PHARMA has recently increased by 55.14%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 8 people have searched for ATYR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added Atyr PHARMA to their MarketBeat watchlist in the last 30 days. This is a decrease of -56% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Atyr PHARMA insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.70% of the stock of Atyr PHARMA is held by insiders.

Percentage Held by Institutions

61.72% of the stock of Atyr PHARMA is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ATYR Stock Analysis - Frequently Asked Questions

How have ATYR shares performed this year?

Atyr PHARMA's stock was trading at $1.74 on January 1st, 2024. Since then, ATYR stock has increased by 74.1% and is now trading at $3.03.
View the best growth stocks for 2024 here.

How were Atyr PHARMA's earnings last quarter?

Atyr PHARMA INC (NASDAQ:ATYR) released its earnings results on Thursday, November, 7th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.01.

How do I buy shares of Atyr PHARMA?

Shares of ATYR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Atyr PHARMA own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Atyr PHARMA investors own include ChargePoint (CHPT), Plug Power (PLUG), Chemomab Therapeutics (CMMB), Curaleaf (CURLF), Daré Bioscience (DARE), Jiuzi (JZXN) and Adial Pharmaceuticals (ADIL).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 11/23/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/13/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ATYR
• Previous Symbol: NASDAQ:ATYR
• CUSIP: N/A
• CIK: 1339970
• Web: N/A
• Phone: (858) 731-8389
• Fax: 858-731-8394
• Employees: 56
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $19.25
• High Stock Price Target: $35.00
• Low Stock Price Target: $9.00
• Potential Upside/Downside: +535.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.94)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-50,390,000.00
• Net Margins: N/A
• Pretax Margin: -27,155.32%
• Return on Equity: -79.44%
• Return on Assets: -59.16%

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 5.41
• Quick Ratio: 5.41

Sales & Book Value

• Annual Sales: $350,000.00
• Price / Sales: 726.68
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.78 per share
• Price / Book: 3.88

Miscellaneous

• Outstanding Shares: 83,940,000
• Free Float: 80,836,000
• Market Cap: $254.34 million
• Optionable: Optionable
• Beta: 1.10